(ABBV) - Analyzing AbbVie's Short Interest
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
Exact Sciences, Quanterix Extend Slide After Medicare Rates
Raymond James Reiterates Market Perform on Exact Sciences
Exact Sciences Analyst Ratings
Looking Into Alnylam Pharmaceuticals's Recent Short Interest
Amgen Stock Slides 5% as Analysts Weigh in on Drug Study Results
AbbVie Announced Results From A New Post-Hoc Analysis From The Measure Up 1 And Measure Up 2 Phase 3 Studies Of Upadacitinib (15 Mg Or 30 Mg) In Patients With Moderate-to-severe Atopic Dermatitis
Here's How Much $1000 Invested In United Therapeutics 5 Years Ago Would Be Worth Today
Top 4 Health Care Stocks That May Keep You Up At Night
United Therapeutics Plans Five Presentations And One Poster Across Its Commercial And Development Portfolio At The CHEST 2024 Annual Meeting
Overweight Quality Stocks With Positive EPS Revision - MS
UCB Gets Expanded FDA Approval for Psoriasis Drug Bimzelx
FDA Says Gilead Issues Voluntary Nationwide Recall Of One Lot Of Veklury For Injection 100 Mg/Vial Due To The Presence Of A Glass Particle
United Therapeutics Analyst Ratings
Sword of Justice! The US FTC sues three major pharmaceutical "middlemen", vows to correct the distorted profit chain.
The USA's FTC announced on its official website that it has filed a lawsuit against three major "pharmacy benefit managers" and their affiliated organizations, accusing them of engaging in anti-competitive and unfair kickback practices. FTC also "clearly stated" in the declaration its deep concern about the roles played by eli lilly and co, novo-nordisk a/s, sanofi, and other insulin pharmaceutical companies, and the competition bureau may recommend prosecuting these pharmaceutical companies in future enforcement actions.
Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years
Spotlight on AbbVie: Analyzing the Surge in Options Activity
Gilead Sciences Unusual Options Activity For September 20